Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.
IPO Year:
Exchange: NASDAQ
Website: precipiodx.com
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4/A - Precipio, Inc. (0001043961) (Issuer)
4/A - Precipio, Inc. (0001043961) (Issuer)
4/A - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4 - Precipio, Inc. (0001043961) (Issuer)
4/A - Precipio, Inc. (0001043961) (Issuer)
4/A - Precipio, Inc. (0001043961) (Issuer)
4/A - Precipio, Inc. (0001043961) (Issuer)
4/A - Precipio, Inc. (0001043961) (Issuer)
Fastest customizable press release news feed in the world
NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces financial results for the first quarter ended March 31, 2026. Below are some of the key financial performance metrics for the Company. Please see the Company's Form 10-Q which was filed today for additional details. Revenue – $6.71M (vs. $6.69M in Q4-2025; $4.93M in Q1-2025). This was comprised of $6.05M in pathology revenue (up from $5.9M in Q4) and $0.66M in product revenue (down from $0.74M in Q4). The product revenue decline is temporary, and was largely driven by delayed shipment to one of the Company's largest product customers, shifting revenue recogn
NEW HAVEN, Conn., May 13, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces that 2025 employee stock options granted to certain members of Precipio's management team vested last week because the Company's Common Stock price increased by more than 400% since the options were granted. As proposed by the Company's Compensation Committee in late 2024, rather than the standard 4-year time-based vesting period, management was offered and agreed to a market-based vesting structure whereby the options fully vest once the Company's share price exceeds a 10-day VWAP of $30.30. At the time of the grant, the share price and the options strike price w
NEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will include remarks on the company's current core businesses, as well as a moderated live Q&A session at the end of the Company remarks. As part of Precipio's ongoing commitment to transparency and shareholder engagement, this call will be the first time the Company will incorporate a dedicated moderated live Q&A session into its quarterly update call. Management looks forward to addressing investor questions and providing additional insight into the Company's performance, strat
NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Listeners interested in submitting questions in advance should email their questions to investors@precipiodx.com and management will do its best to address those questions during the call. A replay of the call will be available approximately 24 hours after the call and may be
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has announced the publication1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio's new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML). According to the publication's authors: "Its ease of use facilitates broad implementation and accessibility across clinical laboratories and resource settings." Ilan Danieli, CEO of Precipio, expanded on these findings. "Our Bloodhound BCR::ABL1 assay is the first and only assay that simultaneously detects and quantifies all fou
NEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial performance metrics for the Company. Revenue Growth – Precipio's revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year. Q4-2025 revenues were $6.7M, an increase of 23% YoY from $5.4M in Q4-2024. Positive Adjusted EBITDA – Precipio will report Adjusted EBITDA of $0.95M for Q4-2025, and $1.23M for the full year 2025. This is compared to Adjusted EBITDA of $0.40M in Q4-2024 and ($1.5M) in full year 2024. Please
NEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has made major strides in cleaning up its balance sheet with two major accomplishments: 1. Major obligation repaid A $1.1 million advance from Change Healthcare ("CHC"), the Company's clearinghouse service for billing claims processing, has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced Precipio and others funds to cover collections shortfalls. In early January 2026, the Company completed its repayment of that advance. Precipio maintains a small loan with the Connecticut Department of Economic and Community Development in the approximate princ
NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio's BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing concordance with two other leading platforms. The study shows clear, positive impacts on patient care alongside substantial improvements in laboratory workflows. Poster presentation of the study abstract, and results discussion are scheduled for Monday December 8th fro
NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The incident was limited to its file storage server and did not impact any of Precipio's operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the company's operations or finances. Upon detecting the activity, the Company immediately initiated its incident response procedures and engaged an external cybersecurity law firm and forensic specialists t
NEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), filed its 10-Q report today. The following are the highlights of the Company's financial performance and outlook for the remainder of 2025. Q3-2025 Financial Results: Revenues. Q3-2025 revenues reached $6.8M, a 30% increase YoY from $5.2M in Q3-2024, and a QoQ increase of 20% from $5.7M in Q2-2025. Pathology Services Division's services revenue increased 20% from the prior quarter; revenues from Product Division customers increased 16% from the prior quarter.Adjusted EBITDA. Q3-2025 Adjusted EBITDA of $469K was up $369K YoY and up more than $500K from Q2-2025, swinging f
10-Q - Precipio, Inc. (0001043961) (Filer)
8-K - Precipio, Inc. (0001043961) (Filer)
DEFA14A - Precipio, Inc. (0001043961) (Filer)
DEF 14A - Precipio, Inc. (0001043961) (Filer)
10-K - Precipio, Inc. (0001043961) (Filer)
8-K - Precipio, Inc. (0001043961) (Filer)
SCHEDULE 13G/A - Precipio, Inc. (0001043961) (Subject)
S-8 - Precipio, Inc. (0001043961) (Filer)
8-K - Precipio, Inc. (0001043961) (Filer)
10-Q - Precipio, Inc. (0001043961) (Filer)
Live Leadership Updates
NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib
SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien
NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f
Live finance-specific insights
NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces financial results for the first quarter ended March 31, 2026. Below are some of the key financial performance metrics for the Company. Please see the Company's Form 10-Q which was filed today for additional details. Revenue – $6.71M (vs. $6.69M in Q4-2025; $4.93M in Q1-2025). This was comprised of $6.05M in pathology revenue (up from $5.9M in Q4) and $0.66M in product revenue (down from $0.74M in Q4). The product revenue decline is temporary, and was largely driven by delayed shipment to one of the Company's largest product customers, shifting revenue recogn
NEW HAVEN, Conn., May 13, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces that 2025 employee stock options granted to certain members of Precipio's management team vested last week because the Company's Common Stock price increased by more than 400% since the options were granted. As proposed by the Company's Compensation Committee in late 2024, rather than the standard 4-year time-based vesting period, management was offered and agreed to a market-based vesting structure whereby the options fully vest once the Company's share price exceeds a 10-day VWAP of $30.30. At the time of the grant, the share price and the options strike price w
NEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will include remarks on the company's current core businesses, as well as a moderated live Q&A session at the end of the Company remarks. As part of Precipio's ongoing commitment to transparency and shareholder engagement, this call will be the first time the Company will incorporate a dedicated moderated live Q&A session into its quarterly update call. Management looks forward to addressing investor questions and providing additional insight into the Company's performance, strat
NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Listeners interested in submitting questions in advance should email their questions to investors@precipiodx.com and management will do its best to address those questions during the call. A replay of the call will be available approximately 24 hours after the call and may be
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has announced the publication1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio's new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML). According to the publication's authors: "Its ease of use facilitates broad implementation and accessibility across clinical laboratories and resource settings." Ilan Danieli, CEO of Precipio, expanded on these findings. "Our Bloodhound BCR::ABL1 assay is the first and only assay that simultaneously detects and quantifies all fou
NEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial performance metrics for the Company. Revenue Growth – Precipio's revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year. Q4-2025 revenues were $6.7M, an increase of 23% YoY from $5.4M in Q4-2024. Positive Adjusted EBITDA – Precipio will report Adjusted EBITDA of $0.95M for Q4-2025, and $1.23M for the full year 2025. This is compared to Adjusted EBITDA of $0.40M in Q4-2024 and ($1.5M) in full year 2024. Please
NEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has made major strides in cleaning up its balance sheet with two major accomplishments: 1. Major obligation repaid A $1.1 million advance from Change Healthcare ("CHC"), the Company's clearinghouse service for billing claims processing, has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced Precipio and others funds to cover collections shortfalls. In early January 2026, the Company completed its repayment of that advance. Precipio maintains a small loan with the Connecticut Department of Economic and Community Development in the approximate princ
NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio's BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing concordance with two other leading platforms. The study shows clear, positive impacts on patient care alongside substantial improvements in laboratory workflows. Poster presentation of the study abstract, and results discussion are scheduled for Monday December 8th fro
NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The incident was limited to its file storage server and did not impact any of Precipio's operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the company's operations or finances. Upon detecting the activity, the Company immediately initiated its incident response procedures and engaged an external cybersecurity law firm and forensic specialists t
NEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), filed its 10-Q report today. The following are the highlights of the Company's financial performance and outlook for the remainder of 2025. Q3-2025 Financial Results: Revenues. Q3-2025 revenues reached $6.8M, a 30% increase YoY from $5.2M in Q3-2024, and a QoQ increase of 20% from $5.7M in Q2-2025. Pathology Services Division's services revenue increased 20% from the prior quarter; revenues from Product Division customers increased 16% from the prior quarter.Adjusted EBITDA. Q3-2025 Adjusted EBITDA of $469K was up $369K YoY and up more than $500K from Q2-2025, swinging f
This live feed shows all institutional transactions in real time.
SC 13G - Precipio, Inc. (0001043961) (Subject)